Interferon alpha induces cell death through interference with interleukin 6 signaling and inhibition of STAT3 activity

Experimental Cell Research

Volumn 313, Issue 19, 2007, Pages 4015-4024

  Thyrell, Lena ^a   Arulampalam, Velmurugesan ^b   Hjortsberg, Linn ^a   Farnebo, Marianne ^a   Grandér, Dan ^a   Pokrovskaja Tamm, Katja ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Apoptosis; IL 6; Interferon; STAT1; STAT3

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 6; PROTEIN BCL XL; PROTEIN MCL 1; STAT1 PROTEIN; STAT3 PROTEIN; STAT3C PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL DEATH; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; DRUG INHIBITION; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; UPREGULATION;

EID: 35448979972     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2007.08.007     Document Type: Article

References (33)

1. Brierley M.M., and Fish E.N. Review: IFN-alpha/beta receptor interactions to biologic outcomes: understanding the circuitry. J. Interferon Cytokine Res. 22 (2002) 835-845
2. Lindner D.J. Interferons as antiangiogenic agents. Curr. Oncol. Rep. 4 (2002) 510-514
3. Minami R., Muta K., Ilseung C., Abe Y., Nishimura J., and Nawata H. Interleukin-6 sensitizes multiple myeloma cell lines for apoptosis induced by interferon-alpha. Exp. Hematol. 28 (2000) 244-255
4. Otsuki T., Yamada O., Sakaguchi H., Tomokuni A., Wada H., Yawata Y., and Ueki A. Human myeloma cell apoptosis induced by interferon-alpha. Br. J. Haematol. 103 (1998) 518-529
5. Sanceau J., Hiscott J., Delattre O., and Wietzerbin J. IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Oncogene 19 (2000) 3372-3383
6. Sangfelt O., Erickson S., Castro J., Heiden T., Einhorn S., and Grander D. Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines. Cell Growth Differ. 8 (1997) 343-352
7. Thyrell L., Erickson S., Zhivotovsky B., Pokrovskaja K., Sangfelt O., Castro J., Einhorn S., and Grander D. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene 21 (2002) 1251-1262
8. Thyrell L., Hjortsberg L., Arulampalam V., Panaretakis T., Uhles S., Dagnell M., Zhivotovsky B., Leibiger I., Grander D., and Pokrovskaja K. Interferon alpha-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway. J. Biol. Chem. 279 (2004) 24152-24162
9. Chawla-Sarkar M., Lindner D.J., Liu Y.F., Williams B.R., Sen G.C., Silverman R.H., and Borden E.C. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8 (2003) 237-249
10. Pokrovskaja K., Panaretakis T., and Grander D. Alternative signaling pathways regulating type I interferon-induced apoptosis. J. Interferon Cytokine Res. 25 (2005) 799-810
11. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Ann. Rev. Biochem. 67 (1998) 227-264
12. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A., and Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332 (1988) 83-85
13. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., and Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374 (2003) 1-20
14. Shen Y., Devgan G., Darnell Jr. J.E., and Bromberg J.F. Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 1543-1548
15. Bromberg J., and Darnell Jr. J.E. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19 (2000) 2468-2473
16. Berger L.C., and Hawley R.G. Interferon-beta interrupts interleukin-6-dependent signaling events in myeloma cells. Blood 89 (1997) 261-271
17. Erickson S., Matikainen S., Thyrell L., Sangfelt O., Julkunen I., Einhorn S., and Grander D. Interferon-alpha inhibits Stat5 DNA-binding in IL-2 stimulated primary T-lymphocytes. Eur. J. Biochem. 269 (2002) 29-37
18. Nilsson K., Bennich H., Johansson S.G., and Ponten J. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin. Exp. Immunol. 7 (1970) 477-489
19. Jernberg H., Nilsson K., Zech L., Lutz D., Nowotny H., and Scheirer W. Establishment and phenotypic characterization of three new human myeloma cell lines (U-1957, U-1958, and U-1996). Blood 69 (1987) 1605-1612
20. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernandez-Luna J.L., Nunez G., Dalton W.S., and Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10 (1999) 105-115
21. Chen Q., Gong B., Mahmoud-Ahmed A.S., Zhou A., Hsi E.D., Hussein M., and Almasan A. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 98 (2001) 2183-2192
22. Gritsko T., Williams A., Turkson J., Kaneko S., Bowman T., Huang M., Nam S., Eweis I., Diaz N., Sullivan D., Yoder S., Enkemann S., Eschrich S., Lee J.H., Beam C.A., Cheng J., Minton S., Muro-Cacho C.A., and Jove R. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 12 (2006) 11-19
23. Crowder C., Dahle O., Davis R.E., Gabrielsen O.S., and Rudikoff S. PML mediates IFN-alpha-induced apoptosis in myeloma by regulating TRAIL induction. Blood 105 (2005) 1280-1287
24. Zhang B., and Fenton R.G. Proliferation of IL-6-independent multiple myeloma does not require the activity of extracellular signal-regulated kinases (ERK1/2). J. Cell. Physiol. 193 (2002) 42-54
25. Anthes J.C., Zhan Z., Gilchrest H., Egan R.W., Siegel M.I., and Billah M.M. Interferon-alpha down-regulates the interleukin-6 receptor in a human multiple myeloma cell line, U266. Biochem. J. 309 Pt 1 (1995) 175-180
26. Schwabe M., Brini A.T., Bosco M.C., Rubboli F., Egawa M., Zhao J., Princler G.L., and Kung H.F. Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains. J. Clin. Invest. 94 (1994) 2317-2325
27. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., and Darnell Jr. J.E. Stat3 as an oncogene. Cell 98 (1999) 295-303
28. Liddle F.J., Alvarez J.V., Poli V., and Frank D.A. Tyrosine phosphorylation is required for functional activation of disulfide-containing constitutively active STAT mutants. Biochemistry 45 (2006) 5599-5605
29. Matsui W., Huff C.A., Vala M., Barber J., Smith B.D., and Jones R.J. Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation. Br. J. Haematol. 121 (2003) 251-258
30. Dimberg L.Y., Dimberg A.I., Ivarsson K., Stromberg T., Osterborg A., Nilsson K., Oberg F., and Wiklund H.J. Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cells. Blood 106 (2005) 1346-1354
31. Stephanou A., Brar B.K., Knight R.A., and Latchman D.S. Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ. 7 (2000) 329-330
32. Hong F., Jaruga B., Kim W.H., Radaeva S., El-Assal O.N., Tian Z., Nguyen V.A., and Gao B. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J. Clin. Invest. 110 (2002) 1503-1513
33. Panaretakis T., Pokrovskaja K., Shoshan M.C., and Grander D. Interferon-alpha-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax. Oncogene 22 (2003) 4543-4556